Free Trial

Phoenix Financial Ltd. Boosts Stake in Danaher Corporation $DHR

Danaher logo with Medical background

Key Points

  • Phoenix Financial Ltd. increased its stake in Danaher Corporation by 32% during the second quarter, owning 8,602 shares valued at approximately $1.7 million.
  • Several institutional investors have significantly increased their positions in Danaher, with GHP Investment Advisors raising its stake by 396% in the first quarter.
  • Analysts have set a new average price target of $245.00 for Danaher, with 17 giving the stock a "Buy" rating while 6 recommended holding.
  • MarketBeat previews top five stocks to own in November.

Phoenix Financial Ltd. raised its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 32.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,602 shares of the conglomerate's stock after purchasing an additional 2,083 shares during the quarter. Phoenix Financial Ltd.'s holdings in Danaher were worth $1,702,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. GHP Investment Advisors Inc. raised its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Sierra Ocean LLC raised its position in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the period. Red Tortoise LLC raised its position in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock valued at $30,000 after purchasing an additional 98 shares during the period. Smallwood Wealth Investment Management LLC purchased a new stake in Danaher in the first quarter valued at $31,000. Finally, Ramirez Asset Management Inc. acquired a new stake in shares of Danaher in the second quarter valued at $40,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DHR. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Evercore ISI lifted their price objective on Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Danaher in a research note on Wednesday, October 8th. Finally, Barclays reaffirmed an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $245.00.

Get Our Latest Report on Danaher

Danaher Trading Up 6.1%

DHR opened at $221.13 on Wednesday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $269.24. The stock has a market capitalization of $158.34 billion, a price-to-earnings ratio of 47.05, a PEG ratio of 3.01 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The business has a fifty day moving average price of $202.07 and a 200 day moving average price of $197.59.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts' expectations of $6 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 11.20% of the company's stock.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.